

Sangamo Therapeutics Logo

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast

February 21, 2019

BRISBANE, Calif., Feb. 21, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, February 28, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.



The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 6875578. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under [Events and Presentations](#). A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 6875578.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-fourth-quarter-and-full-year-2018-conference-call-and-webcast-300799927.html>

SOURCE Sangamo Therapeutics, Inc.

Investor Relations - United States, McDavid Stilwell, 510-970-6000, x219, mstilwell@sangamo.com, Varant Shirvanian, 510-970-6000 x205, vshirvanian@sangamo.com, or Media Inquiries - United States, Aron Feingold, 510-970-6000, x421, afeingold@sangamo.com, or Investor Relations and Media Inquiries - European Union, or Caroline Courme, 33 4 97 21 27 27, ccourme@sangamo.com